Inspira to Present at the H.C. Wainwright 7th Annual Israel Virtual Conference

Rhea-AI Summary

Inspira Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) announced that Co-Founder and CFO Joe Hayon will present at the H.C. Wainwright 7th Annual Israel Virtual Conference on November 15 at 2:30 PM EST. One-on-one meetings are available for attendees. A replay of the presentation will be accessible on Inspira's investor relations page post-event. Inspira Technologies is developing the ART device, an innovative respiratory support system designed to act as an 'Artificial Lung' for patients, though it has yet to be tested in humans and is not FDA-approved.

RA'ANANA, Israel, Nov. 12, 2021 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (NASDAQ: IINNW) (the "Company" or "Inspira Technologies"), a groundbreaking respiratory support technology company, today announced that Joe Hayon, Co-Founder and Chief Financial Officer, will present at the H.C. Wainwright 7th Annual Israel Virtual Conference.

Joe Hayon will present on November 15 at 2:30pm EST. He will be available for one-on-one meetings on the same day. To schedule a meeting, contact your H.C. Wainwright representative. A replay of the presentation will be available on the company's investor relations page following the event.

For more information regarding these events, please visit Inspira's Investor Relations page here.  

About Inspira Technologies OXY B.H.N. Ltd.

Inspira Technologies is an innovative medical device company in the respiratory care industry. Inspira is developing the ART device, a cost effective early extracorporeal respiratory support system with an intent to function as an "Artificial Lung" for deteriorating respiratory patients. The ART device designed to utilize a hemo-protective flow approach aimed to rebalance saturation levels while patients are awake and breathing, potentially minimizing the patient's need for mechanical ventilation. The Company's product has not yet been tested or used in humans and has not been approved by the U.S. Food and Drug Administration (FDA).

For more information, please visit our corporate website: www.inspirao2.com

For more details:
Miri Segal, Investor Relations, MS-IR LLC
+917-607-8654, msegal@ms-ir.com

View original content:https://www.prnewswire.com/news-releases/inspira-to-present-at-the-hc-wainwright-7th-annual-israel-virtual-conference-301422896.html

SOURCE Inspira Technologies

FAQ

When is Inspira Technologies presenting at the H.C. Wainwright 7th Annual Israel Virtual Conference?

Inspira Technologies will present on November 15 at 2:30 PM EST.

Who is presenting for Inspira Technologies at the conference?

Joe Hayon, Co-Founder and CFO, will present for Inspira Technologies.

Where can I watch the replay of Inspira Technologies' presentation?

The replay will be available on Inspira Technologies' investor relations page after the event.

What is the focus of Inspira Technologies' ART device?

The ART device aims to function as an 'Artificial Lung' for patients with deteriorating respiratory conditions.

Is the ART device approved by the FDA?

No, the ART device has not yet been tested in humans and is not FDA-approved.